Triple Negative Breast Neoplasms: all 1,163 studies

Page 9 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid TumoursActive, not recruitingNCT05057013Phase 1/2
• P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .WithdrawnNCT05008510Phase 2
• Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) StudyActive, not recruitingNCT04993625Not applicable
• Olinvacimab With Pembrolizumab in Patients With mTNBCTerminatedNCT04986852Phase 2
• Study of XB002 in Subjects With Solid Tumors (JEWEL-101)CompletedNCT04925284Phase 1
• Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
• The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
• Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerActive, not recruitingNCT04837209Phase 2
• PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBCStatus unknownNCT04809779Phase 2
• CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04807192Phase 2
• Multiparametric MRI as a Non-Invasive Biomarker of the Tumor MicroenviromentSuspendedNCT04803084
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT04799249Phase 3
• Talazoparib Maintenance Therapy in Triple-negative Breast CancerStatus unknownNCT04755868Phase 2
• A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast CancerStatus unknownNCT04750382Phase 1/2
• Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast CancerStatus unknownNCT04745975Phase 2
• Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT04742959Phase 1/2
• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)TerminatedNCT04726332Phase 1
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedNCT04725331Phase 1/2
• TH1902 in Patients With Advanced Solid TumorsActive, not recruitingNCT04706962Phase 1
• A Study of PY314 in Subjects With Advanced Solid TumorsTerminatedNCT04691375Phase 1
• Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)Status unknownNCT04676997Phase 2
• Psychological Factors and Oncological Outcomes of Triple-negative Breast CancerStatus unknownNCT04669522
• Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBCCompletedNCT04664972Phase 2
• The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBCCompletedNCT04664829Phase 1
• ARGONAUT: Stool and Blood Sample Bank for Cancer PatientsSuspendedNCT04638751
• Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast CancerStatus unknownNCT04634747Phase 2
• A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)CompletedNCT04613674Phase 3
• ImmunoBreast - A Phase Ib StudyStatus unknownNCT04609215Phase 1/2
• A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsActive, not recruitingNCT04606472Phase 1
• ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerWithdrawnNCT04602117Phase 1
• Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast CancerCompletedNCT04596150Phase 2
• Sacituzumab Govitecan in Primary HER2-negative Breast CancerActive, not recruitingNCT04595565Phase 3
• A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast CancerCompletedNCT04584112Phase 1
• Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and ChemotherapyStatus unknownNCT04582955Not applicable
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesActive, not recruitingNCT04561362Phase 1/2
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingNCT04556773Phase 1
• Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast CancerTerminatedNCT04549584
• First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC PatientsCompletedNCT04537286Phase 2
• Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)Status unknownNCT04517292Phase 2
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
• Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsStatus unknownNCT04502680Phase 2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
• Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT04464174Phase 2
• CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NACStatus unknownNCT04457700
• Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsActive, not recruitingNCT04454437Phase 2
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyActive, not recruitingNCT04445844Phase 2
• Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)Active, not recruitingNCT04443348Phase 2
• NBE-002 in Patients With Advanced Solid TumorsTerminatedNCT04441099Phase 1/2
• Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer PatientsActive, not recruitingNCT04438681
• AN0025 and Pembrolizumab Combination in Advanced Solid TumorsActive, not recruitingNCT04432857Phase 1
• Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1
• Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer PatientsStatus unknownNCT04418154Phase 2
• First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCCompletedNCT04408118Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)Status unknownNCT04405505Phase 3
• Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast CancerStatus unknownNCT04403529Phase 3
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BCCompletedNCT04368468
• Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer AdenocarcinomaActive, not recruitingNCT04365790
• Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast CancerStatus unknownNCT04362462
• PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerActive, not recruitingNCT04360941Phase 1
• Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsTerminatedNCT04348916Phase 1
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.TerminatedNCT04335006Phase 3
• [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast CancersCompletedNCT04320030Phase 2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• A Compassionate Use Study of Leronlimab in Breast CancerNo longer availableNCT04313075
• A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant ChemotherapyStatus unknownNCT04297267Phase 2
• Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)Active, not recruitingNCT04296175Phase 3
• Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White WomenWithdrawnNCT04291950
• Bisphenol and Phthalate Exposures in Triple Negative Breast CancerWithdrawnNCT04268693
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersTerminatedNCT04260802Phase 1/2
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine ProfileSuspendedNCT04250818
• Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerWithdrawnNCT04249167Early Phase 1
• Calorie Restriction With or Without Metformin in Triple Negative Breast CancerStatus unknownNCT04248998Phase 2
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesTerminatedNCT04244552Phase 1
• Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast CancerCompletedNCT04224922Phase 2
• SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast CancerStatus unknownNCT04213898Phase 1/2
• Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast CancerStatus unknownNCT04192903Phase 2
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionActive, not recruitingNCT04180371Phase 1/2
• A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Phase 1
• A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast CancerWithdrawnNCT04149444Phase 2
• Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer PatientsStatus unknownNCT04145947
• Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid TumorsStatus unknownNCT04142931Phase 1
• Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast CancerWithdrawnNCT04142554Phase 1
• Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerCompletedNCT04134884Phase 1
• A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Status unknownNCT04129996Phase 2
• Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)CompletedNCT04118062Not applicable
• Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid TumourStatus unknownNCT04107142Phase 1
• Breast Cancer Neoantigen Vaccination With Autologous Dendritic CellsCompletedNCT04105582Phase 1
• Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Phase 3
• Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast CancerActive, not recruitingNCT04083963Phase 2
• Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer PatientsActive, not recruitingNCT04068623
• Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBCWithdrawnNCT04067102Not applicable

← Triple Negative Breast Neoplasms overview